

## Stability Analysis of HBV Epidemic Model with Non-Monotonic Incidence Function

A.K. Dotia<sup>1</sup>, M.O. Ibrahim<sup>2</sup>, K.A. Bello<sup>2</sup>, B.M. Yisa<sup>2</sup>, and B.M. Ahmed<sup>2</sup>.

<sup>1</sup>Department of Mathematics, Kwara State Polytechnic, Ilorin, Nigeria

<sup>2</sup>Department of Mathematics, University of Ilorin, Ilorin, Nigeria.

### Abstract

In this paper, we present an hepatitis B model with non-monotonic incidence function. The model, which is of the form of system of nonlinear differential equations, are constructed. This epidemic model is investigated for different classes of infectious diseases that can be transmitted through an effective contact with an infective individuals, who are contagious (symptomatic and asymptomatic carrier). Mathematical analysis are carried out, that determines the equilibria solutions and the stability analysis of the equilibria of the model, using nonlinear Lyapunov function of Goh-Volterra type. In addition, we obtained the numerical simulation to verify the model predictions. The result suggest that the endemic nature of the model is approaching equilibrium with increase immunization program and other control measures put in place

**Keywords:** Hepatitis B, endemic, stability, equilibrium

### 1.0 Introduction

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV), Edmund et al. (1993). It is a major global health problem and the most serious type of viral hepatitis. Originally known as "serum hepatitis", the disease has caused epidemics in parts of Asia and Africa, and it is endemic in China (Williams, 2006). About a third of the world population has been infected at one point in their lives, including 350 million who are chronic carriers which causes 620,000 deaths worldwide each year (WHO, 2004). If your body is able to fight off the hepatitis B infection, any symptoms that you had should go away over a period

of weeks to months, this is termed acute hepatitis B. Some people's bodies are not able to completely get rid of the hepatitis B infection. This is called chronic hepatitis B.

Hepatitis is an inflammation of the liver caused by viruses, bacterial infections, or continuous exposure to alcohol, drugs, or toxic chemicals, such as those found in aerosol sprays and paint thinners (Ganem, D., Prince, A. M. 2004). Inflammation is the painful, red swelling that results when tissues of the body become injured or infected. Inflammation can cause organs to not work properly. Hepatitis can also result from an autoimmune disorder, in which the body mistakenly sends disease-fighting cells to attack its own healthy tissue, in this case the liver (Barker et al., 1996). The liver is located in the upper right hand side of the abdomen, mostly behind the rib cage. The liver of an adult normally weighs close to three pounds (Chang, June 2007). No matter what its cause, hepatitis reduces the liver's ability to perform life-preserving functions, including filtering harmful infectious agents from the blood, storing blood sugar and converting it to usable energy forms, and producing many proteins necessary for life (Edmund et al., 1993).

In many developed countries (e.g. those in Western Europe and North America), patterns of transmission are different from those in developing countries. The majority of infections in developed countries are transmitted during young adulthood by sexual activity, tattoo or acupuncture with unclean needles and instruments, and injecting drug use (Gane, E. 2005). Hepatitis B is a major infectious occupational hazard of health workers (Barker et al., 1996). The hepatitis B virus is not spread by contaminated food or water, and cannot be spread casually in the workplace (McMahon et al. 1985).

Corresponding author: A.K. Dotia, E-mail: oe.oyewande@ui.edu.ng, Tel.: +2348077697136


## 2.0 Mathematical Model Formulation

A detailed understanding of the transmission of the hepatitis B virus and other emerging pathogens is crucial in its containment (Goldstein, et al., 2005). Mathematical models can give insight into potential impact interventions (Hou, et al., 2005). The complex interaction of different infection control strategies and their likely impact on transmission can be predicted using mathematical models (Wang, et al., 2004).

We propose a mathematical model to understand the transmission dynamics and prevalence of HBV. The model is constructed based on the characteristics of HBV transmission and the model of L. Zou et al. (2010). Note that L. Zou et al. (2010) considered only six epidemiological groups and did not distinguish the infective class into subgroups. In fact, the immunity after recovery is lifetime, while that following vaccination might wane after some time (Edmunds et al., 1996b). Therefore, we divide the host population into seven epidemiological groups: the proportion susceptible to infection  $S$ ; those latently infected  $E$ ; uneducated acute infections  $I_u$ ; educated acute infections  $I_e$ ; carriers  $C$ ; recovered  $R$ ; and Vaccinated  $V$ . We assume that the population of newborn carriers born to carriers is less than the sum of the death of carriers and the population moving from carrier to immune state. In this case we have  $\mu\omega vC < \mu_0 + \mu_1 + \gamma_2$ .

Otherwise, carriers would keep increasing rapidly as long as there is infection (Lan Zou et al. 2010); i.e.,  $\frac{dC}{dt} > 0$  for

$C \neq 0$  or  $I \neq 0$  and  $t \geq 0$ : The model is given by seven ordinary differential equations:



$$\frac{dS}{dt} = \mu\omega(1-vC) + \psi V - [\mu_0 + \lambda + \epsilon\beta C + \gamma_3]S \quad (2.1)$$

$$\frac{dE}{dt} = [\lambda + \epsilon\beta C]S - (\mu_0 + \sigma)E \quad (2.2)$$

$$\frac{dI_u}{dt} = \sigma E - (\mu_0 + 2\gamma_0)I_u \quad (2.3)$$

$$\frac{dI_e}{dt} = \gamma_0 I_u - (\mu_0 + \gamma_1)I_e \quad (2.4)$$

$$\frac{dC}{dt} = \mu\omega vC + q(\gamma_0 I_u + \gamma_1 I_e) - (\mu_0 + \mu_1 + \gamma_2)C \quad (2.5)$$

$$\frac{dR}{dt} = \gamma_2 C + (1-q)(\gamma_0 I_u + \gamma_1 I_e) - \mu_0 R \quad (2.6)$$

$$\frac{dV}{dt} = \mu(1-\omega) + \gamma_3 S - (\mu_0 + \psi)V \quad (2.7)$$

Where

$$\lambda = \beta \left( \frac{I_u}{1 + \alpha_1 I_u} + \frac{\eta I_e}{1 + \alpha_2 I_e} \right)$$

In this model, the Holling-type II incidence function given by

$$g(I) = \frac{\beta I}{1 + \omega I}$$

The choice of this incidence function is necessary due to the preventive measure (and behavioral changes) taken by the susceptible individuals in response to the severity of the disease.

## 2.1 The Parameters Used are Defined Below

$\mu$  is the birth rate,  $\mu_0$  is the Natural mortality rate,  $\mu_1$  is the HBV related mortality rate

$\omega$  = proportion of birth without successful vaccination

$\beta$  = Transmission coefficient or effective contact rate

$\varepsilon$  = Reduced transmission rate

$\sigma$  = Rate of movement from latent to uncounsel acute

$\gamma_0$  = Rate of movement from uncounsel acute to counsel acute

$\gamma_1$  = Rate of movement from counsel acute to carrier

$\gamma_2$  = Rate of movement from carrier to immune

$\gamma_3$  = vaccination rate

$q$  = Average probability an individual fail to clear an acute infection and develops to carrier state

$\psi$  = Rate of waning vaccine-induced immunity

$v$  = Proportion of perinatally infected (carrier mothers)

The total population  $N(t)$  can be obtained from the model;

$$N(t) = S(t) + E(t) + I_u(t) + I_e(t) + C(t) + R(t) + V(t)$$

$$\frac{dN}{dt} = \mu - N\mu_0 - \mu_1 C \quad (2.8)$$

Here, it is important to note that in the absence of the disease  $N(t) \rightarrow \frac{\mu}{\mu_0}$ . Moreover, under the dynamics described by the

above systems of equations, the region.

$\Omega = \{x = (S, E, I_u, I_e, C, V, N) \in \mathbb{R}_+^7 \mid S \geq 0, E \geq 0, I_u \geq 0, I_e \geq 0, C \geq 0, V \leq N \leq \frac{\mu}{\mu_0}\}$ , is positively

invariant. Hence the system is both mathematically and epidemiologically well-posed. Therefore, for initial starting point  $x \in \mathbb{R}_+^7$ , the trajectory lies in  $\Omega$ . Thus we restrict our analysis to the region  $\Omega$ . (where the model make biological sense).

**Lemma:** The basic reproduction number for our model system (2.1) to (2.7) is

$$R_0 = \frac{\beta S_0 \sigma}{k_0 k_1} + \frac{\beta S_0 \gamma_0 \sigma}{k_0 k_1 k_2} + \frac{\varepsilon \beta S_0 q \gamma_0 \sigma (k_2 + \gamma_1)}{k_0 k_1 k_2 k_3}$$

where

$$R_0 = \frac{\beta \mu (\mu_0 \omega + \psi) \sigma ((\mu_0 + \gamma_1) q \varepsilon \gamma_0 + q \varepsilon \gamma_0 \gamma_1 + (\mu_0 + \gamma_1) (-\mu \omega v + \mu_0 + \mu_1 + \gamma_2) + (-\mu \omega v + \mu_0 + \mu_1 + \gamma_2) \gamma_0)}{\mu_0 (\mu_0 + \gamma_3 + \psi) (\mu_0 + \gamma_1) (\mu_0 + 2\gamma_0) (\mu_0 + \sigma) (-\mu \omega v + \mu_0 + \mu_1 + \gamma_2)} \quad (2.9)$$

The simulations were done using MAPLE program. We use some parameters from literature for our model in equation (2.1) - (2.7) as follows;  $\mu = 0.0121$ ,  $\mu_0 = 0.00693$ ,  $\mu_1 = 0.2$  percent,  $\beta$  = from 0.95 to 20.49,  $\varepsilon = 0.16$ ,  $\sigma = 6$  per year,  $\gamma_0 = 4$  per year,  $\gamma_1 = 2$  per year,  $\gamma_2 = 0.025$  per year,  $\gamma_3 = 0 - 100$  percent,  $\omega = 0 - 100$  percent,  $q = 0.885$ ,  $\psi = 0.1$ ,  $v = 0.11$ . We calculate the basic reproduction number as  $R_0 = 3.961482318$ .

### 3.0 Stability Analysis

In our attempt on the steady state analysis, we consider the reduced following system, because R appears only in the sixth equation:

$$\frac{dS}{dt} = \mu\omega(1-\nu C) + \psi V - [\mu_0 + \lambda + \varepsilon\beta C + \gamma_3]S \quad (3.1)$$

$$\frac{dE}{dt} = [\lambda + \varepsilon\beta C]S - (\mu_0 + \sigma)E \quad (3.2)$$

$$\frac{dI_u}{dt} = \sigma E - (\mu_0 + 2\gamma_0)I_u \quad (3.3)$$

$$\frac{dI_e}{dt} = \gamma_0 I_u - (\mu_0 + \gamma_1)I_e \quad (3.4)$$

$$\frac{dC}{dt} = \mu\omega\nu C + q(\gamma_0 I_u + \gamma_1 I_e) - (\mu_0 + \mu_1 + \gamma_2)C \quad (3.5)$$

$$\frac{dV}{dt} = \mu(1-\omega) + \gamma_3 S - (\mu_0 + \psi)V \quad (3.6)$$

### 3.1 Equilibrium Solutions

The system equation (3.1 - 3.6) has two equilibrium solutions:

(1) a disease free equilibrium solution

$$E_0^{dfe} = (S_0, 0, 0, 0, 0, V_0),$$

where

$$S_0 = \frac{\mu(\mu_0\omega + \psi)}{\mu_0(\mu_0 + \gamma_3 + \psi)}, \quad V_0 = \frac{\mu(\mu_0 + \gamma_3 - \mu_0\omega)}{\mu_0(\mu_0 + \gamma_3 + \psi)} \quad (3.1.1)$$

(2) an endemic equilibrium solution

if  $R_0 > 1$ , where

$$E_*^{ec} = (S^{**}, E^{**}, I_u^{**}, I_e^{**}, C^{**}, V^{**}),$$

$$S^{**} = \frac{(\mu_0 + \sigma)(\mu_0 + 2\gamma_0)(\mu_0 + \gamma_1)}{\beta\gamma_0\sigma} \left( \frac{(\mu_0 + \gamma_1)}{(\mu_0 + \gamma_1)\alpha_1 I_e^{**} + \gamma_0} + \frac{\eta}{\alpha_2 I_e^{**} + 1} + \frac{\varepsilon q(\mu_0 + 2\gamma_1)}{-\mu\omega\nu + \mu_0 + \mu_1 + \gamma_2} \right)^{-1} \quad (3.1.2)$$

$$E^{**} = \frac{(\mu_0 + 2\gamma_0)(\mu_0 + \gamma_1)I_e^{**}}{\gamma_0\sigma} \quad (3.1.3)$$

$$I_e^{**} = \frac{\gamma_0 I_u^{**}}{(\mu_0 + \gamma_1)} \quad (3.1.4)$$

$$I_u^{**} = \frac{(\mu_0 + \gamma_1)I_e^{**}}{\gamma_0} \quad (3.1.5)$$

$$C^{**} = \frac{qI_u^{**}(\mu_0 + 2\gamma_1)}{-\mu\omega\nu + \mu_0 + \mu_1 + \gamma_2} \quad (3.1.6)$$

$$V^{**} = \frac{-\mu(1-\omega) - \gamma_3 S^{**}}{-\mu_0 - \psi} \quad (3.1.7)$$

**3.2 Local Stability of the Equilibria**

**Theorem 1** The disease free equilibrium is locally asymptotically stable if  $R_0 < 1$ .

**Proof**

The Jacobian matrix of the system of equations is given in the form;

Evaluating the above at disease free, the Variational (Jacobian) matrix becomes:

(3.2.1)

$$J_0 = \begin{pmatrix} -\mu_0 - \gamma_3 & 0 & -\beta S & -\eta \beta S & -\varepsilon \beta S - \mu \omega v & \psi \\ 0 & -\mu - \sigma & \beta S & \eta \beta S & \varepsilon \beta S & 0 \\ 0 & \sigma & -\mu_0 - 2\gamma_0 & 0 & 0 & 0 \\ 0 & 0 & \gamma_0 & -\mu_0 - \gamma_1 & 0 & 0 \\ 0 & 0 & q\gamma_0 & q\gamma_1 & -(\mu \omega v + \mu_0 + \mu_1 + \gamma_2) & 0 \\ \gamma_3 & 0 & 0 & 0 & 0 & -\mu_0 - \psi \end{pmatrix}$$

$$J^* = \begin{pmatrix} -\mu_0 - \beta \left( \frac{I_u}{\alpha_1 I_u + 1} + \frac{\eta I_e}{\alpha_2 I_e + 1} \right) - \varepsilon \beta C - \gamma_3 & 0 & \frac{-\beta S}{(\alpha_1 I_u + 1)^2} & \frac{-\eta \beta S}{(\alpha_1 I_u + 1)^2} & -\varepsilon \beta S - \mu \omega v & \psi \\ \beta \left( \frac{I_u}{\alpha_1 I_u + 1} + \frac{\eta I_e}{\alpha_2 I_e + 1} \right) - \varepsilon \beta C & -\mu - \sigma & \frac{\beta S}{(\alpha_1 I_u + 1)^2} & \frac{\eta \beta S}{(\alpha_1 I_u + 1)^2} & \varepsilon \beta S & 0 \\ 0 & \sigma & -\mu_0 - 2\gamma_0 & 0 & 0 & 0 \\ 0 & 0 & \gamma_0 & -\mu_0 - \gamma_1 & 0 & 0 \\ 0 & 0 & q\gamma_0 & q\gamma_1 & -(\mu \omega v + \mu_0 + \mu_1 + \gamma_2) & 0 \\ \gamma_3 & 0 & 0 & 0 & 0 & -\mu_0 - \psi \end{pmatrix}$$

(3.2.2)

The eigen-values of the matrix  $J_0$  are;

$$\lambda_1 = -k_5, \quad \lambda_2 = -\frac{k_4 k_5 - \psi \gamma_3}{k_5}, \quad \lambda_3 = -k_0, \quad \lambda_4 = \frac{T\sigma - k_0 k_1}{k_0},$$

for  $\lambda_4$  to be negative,

$$\lambda_5 = -\frac{T\eta \sigma k_1 + T\sigma k_2 - k_0 k_1 k_3}{T\sigma - k_0 k_1}, \quad \lambda_6 = -\frac{T\sigma \varepsilon k_1 q \gamma_1 + T\sigma \varepsilon k_2 q \gamma_0 - T\eta \sigma k_1 k_3 - T\eta \sigma k_2 k_3 - k_0 k_1 k_2 k_3}{T\eta \sigma k_1 + T\sigma k_2 - k_0 k_1 k_2}$$

$$\lambda_4 < 0 \Rightarrow T\sigma - k_0 k_1 < 0 \Rightarrow -k_0 k_1 < -T\sigma \Rightarrow k_0 k_1 > T\sigma \quad (\mu_0 + 2\sigma)(\mu_0 + \gamma_0 + \alpha_1) > \beta S \sigma$$

If all the eigenvalues are negative, then  $R_0 < 1$ , and the disease-free equilibrium is locally asymptotically stable.

**Theorem 2**

The endemic equilibrium is locally asymptotically stable if  $R_0 > 1$ .

**Proof**

The Jacobian matrix of the system of equations is given in the form;

(3.2.3)

the above can be rewritten as;

$$\begin{pmatrix}
 -\mu_0 - \beta \left( \frac{l_u}{\alpha_1 l_u + 1} + \frac{\eta l_c}{\alpha_2 l_c + 1} \right) - \varepsilon \beta C - \gamma_3 & 0 & \frac{-\beta S}{(\alpha_1 l_u + 1)^2} & \frac{-\eta \beta S}{(\alpha_2 l_c + 1)^2} & -\varepsilon \beta S - \mu \omega \nu & \psi \\
 \beta \left( \frac{l_u}{\alpha_1 l_u + 1} + \frac{\eta l_c}{\alpha_2 l_c + 1} \right) - \varepsilon \beta C & -\mu - \sigma & \frac{\beta S}{(\alpha_1 l_u + 1)^2} & \frac{\eta \beta S}{(\alpha_2 l_c + 1)^2} & \varepsilon \beta S & 0 \\
 0 & \sigma & -\mu_0 - 2\gamma_0 & 0 & 0 & 0 \\
 0 & 0 & \gamma_0 & -\mu_0 - \gamma_1 & 0 & 0 \\
 0 & 0 & q\gamma_0 & q\gamma_1 & -(\mu \omega \nu + \mu_0 + \mu_1 + \gamma_2) & 0 \\
 \gamma_3 & 0 & 0 & 0 & 0 & -\mu_0 - \psi
 \end{pmatrix} \quad (3.2.4)$$

Reducing the rows using an elementary row-transformation into upper echelon's form

$$J^* = \begin{pmatrix}
 -k_5 & 0 & -T_1 & -\eta T_2 & -k_6 & \psi \\
 k_7 & -k_0 & T_1 & \eta T_2 & \varepsilon T_3 & 0 \\
 0 & \sigma & -k_1 & 0 & 0 & 0 \\
 0 & 0 & \gamma_0 & -k_2 & 0 & 0 \\
 0 & 0 & q\gamma_0 & q\gamma_1 & -k_3 & 0 \\
 \gamma_3 & 0 & 0 & 0 & 0 & -k_4
 \end{pmatrix} \quad J^* = \begin{pmatrix}
 -k_5 & 0 & -T_1 & -\eta T_2 & -k_6 & \psi \\
 0 & -k_0 & M_{23} & M_{24} & M_{25} & M_{26} \\
 0 & 0 & M_{33} & M_{34} & M_{35} & M_{36} \\
 0 & 0 & 0 & -M_{44} & -M_{45} & -M_{46} \\
 0 & 0 & 0 & 0 & -M_{55} & -M_{56} \\
 0 & 0 & 0 & 0 & 0 & -M_{66}
 \end{pmatrix} \quad (3.2.5)$$

Where

$$\begin{aligned}
 M_{23} &= \frac{T_1(k_5 - k_7)}{k_5}, \quad M_{24} = \frac{T_2(k_5 - k_7)}{k_5}, \quad M_{25} = \frac{\varepsilon T_3 k_5 - k_7 k_6}{k_5}, \quad M_{26} = \frac{k_7 \psi}{k_5} \\
 M_{33} &= \frac{\sigma T_1 k_5 - \sigma T_1 k_7 - k_1 k_0 k_5}{k_0 k_5}, \quad M_{34} = \frac{\sigma \eta T_2 (k_5 - k_7)}{k_0 k_5}, \quad M_{35} = \frac{\sigma (\varepsilon T_3 k_5 - k_7 k_6)}{k_0 k_5}, \quad M_{36} = \frac{\sigma k_7 \psi}{k_0 k_5} \\
 M_{44} &= \frac{\gamma_0 \sigma \eta T_2 k_5 - \gamma_0 \sigma \eta T_2 k_7 + T_1 k_2 k_5 \sigma - T_1 k_2 k_7 \sigma - k_1 k_0 k_2 k_5}{T_1 k_5 \sigma - T_1 k_7 \sigma - k_1 k_0 k_5}, \quad M_{45} = \frac{\gamma_0 \sigma (\varepsilon T_3 k_5 - k_7 k_6)}{\sigma T_1 k_5 - \sigma T_1 k_7 - k_0 k_1 k_5} \\
 M_{46} &= \frac{\gamma_0 \sigma k_7 \psi}{T_1 k_5 \sigma - T_1 k_7 \sigma - k_1 k_0 k_5} \\
 M_{55} &= \frac{\left\{ T_1 k_2 \sigma k_3 k_5 - T_1 k_2 \sigma k_3 k_7 + T_3 k_2 k_5 q \sigma \varepsilon \gamma_0 + T_3 k_5 q \sigma \varepsilon \gamma_0 \gamma_1 + T_2 \eta k_3 k_5 \sigma \gamma_0 \right.}{\eta \gamma_0 T_2 k_5 \sigma - \eta \gamma_0 T_2 k_7 \sigma - T_1 k_2 k_7 \sigma - k_1 k_0 k_2 k_5} \\
 &\quad \left. - k_1 k_0 k_2 k_3 k_5 - T_2 \eta k_3 k_7 \sigma \gamma_0 - k_2 k_6 k_7 q \sigma \gamma_0 - k_6 k_7 q \sigma \gamma_0 \gamma_1 \right\}} \\
 M_{56} &= \frac{(k_2 + \gamma_1) q \gamma_0 \sigma k_7 \psi}{\eta \gamma_0 T_2 k_5 \sigma - \eta \gamma_0 T_2 k_7 \sigma - T_1 k_2 k_7 \sigma - k_1 k_0 k_2 k_5} \\
 M_{66} &= \frac{\left\{ T_1 k_2 \sigma k_3 k_4 k_5 - T_1 k_2 \sigma k_3 k_4 k_7 - T_1 k_2 \sigma k_3 \psi \gamma_3 + T_3 k_2 k_4 k_5 q \sigma \varepsilon \gamma_0 + T_3 k_2 \psi q \sigma \varepsilon \gamma_0 \gamma_3 \right.}{\left\{ T_1 k_2 \sigma k_3 k_5 - T_1 k_2 \sigma k_3 k_7 + T_3 k_2 k_5 q \sigma \varepsilon \gamma_0 + T_3 k_5 q \sigma \varepsilon \gamma_0 \gamma_1 + T_2 \eta k_3 k_5 \sigma \gamma_0 \right.} \\
 &\quad \left. - k_2 k_4 k_6 k_7 q \sigma \gamma_0 - k_1 k_0 k_2 k_3 k_4 k_5 + k_1 k_0 k_2 k_3 \psi \gamma_3 + T_3 k_4 k_5 q \sigma \varepsilon \gamma_0 \gamma_1 - T_2 \eta k_3 k_4 k_5 \sigma \gamma_0 \right.} \\
 &\quad \left. - T_3 \psi q \sigma \varepsilon \gamma_0 \gamma_3 - T_2 \eta k_3 k_4 k_7 \sigma \gamma_0 - T_2 \eta k_3 \psi \sigma \gamma_0 \gamma_3 - k_4 k_6 k_7 q \sigma \gamma_0 \gamma_1 \right\}} \\
 &\quad \left\{ T_1 k_2 \sigma k_3 k_5 - T_1 k_2 \sigma k_3 k_7 + T_3 k_2 k_5 q \sigma \varepsilon \gamma_0 + T_3 k_5 q \sigma \varepsilon \gamma_0 \gamma_1 + T_2 \eta k_3 k_5 \sigma \gamma_0 \right\} \\
 &\quad \left. - T_2 \eta k_3 k_7 \sigma \gamma_0 - k_2 k_6 k_7 q \sigma \gamma_0 - k_1 k_0 k_2 k_3 k_5 - k_6 k_7 q \sigma \gamma_0 \gamma_1 \right\}
 \end{aligned}$$

The eigenvalues are;  $\lambda_1 = -k_3$ ,  $\lambda_2 = -k_0$ ,  $\lambda_3 = M_{33}$ ,  $\lambda_4 = -M_{44}$ ,  $\lambda_5 = -M_{55}$ ,  $\lambda_6 = -M_{66}$  for  $\lambda_3$  to be negative,  $\lambda_3 < 0 \Rightarrow \sigma T_1 k_5 - \sigma T k_7 - k_1 k_0 k_5 < 0 \Rightarrow \sigma T_1 k_5 < \sigma T k_7 + k_1 k_0 k_5$  i.e.  $\sigma T k_7 + k_1 k_0 k_5 > \sigma T_1 k_5$ . If all the eigenvalues are negative, then  $R_0 > 1$ , and the endemic equilibrium is locally asymptotically stable.

### 3.3 Global Stability

**Theorem 3** The disease free equilibrium DFE of the model (3.1-3.6), is globally asymptotically stable GAS in  $\Omega$ , whenever  $R_0 \leq 1$ .

**Proof**

Consider the following Lyapunov function:

$$F = \left[ \frac{\sigma k_2 k_3 + \sigma \eta k_3 \gamma_0 + \varepsilon q \sigma \gamma_0 (k_2 + \gamma_1)}{\varepsilon k_0 k_1 k_2} \right] E + \left[ \frac{k_2 k_3 + \eta k_3 \gamma_0 + \varepsilon q \gamma_0 (k_2 + \gamma_1)}{\varepsilon k_1 k_2} \right] I_u + \left[ \frac{k_0 k_1 + (\eta k_3 + \varepsilon q \gamma_1)}{\varepsilon k_0 k_1 k_2} \right] I_e + C \quad (3.3.1)$$

the dot represents differentiation with respect to time, given by

$$\begin{aligned} \dot{F} &= \left[ \frac{\sigma k_2 k_3 + \sigma \eta k_3 \gamma_0 + \varepsilon q \sigma \gamma_0 (k_2 + \gamma_1)}{\varepsilon k_0 k_1 k_2} \right] \dot{E} + \left[ \frac{k_2 k_3 + \eta k_3 \gamma_0 + \varepsilon q \gamma_0 (k_2 + \gamma_1)}{\varepsilon k_1 k_2} \right] \dot{I}_u + \left[ \frac{k_0 k_1 + (\eta k_3 + \varepsilon q \gamma_1)}{\varepsilon k_0 k_1 k_2} \right] \dot{I}_e + \dot{C} \\ &= \left[ \frac{\sigma k_2 k_3 + \sigma \eta k_3 \gamma_0 + \varepsilon q \sigma \gamma_0 (k_2 + \gamma_1)}{\varepsilon k_0 k_1 k_2} \right] \left[ \beta S_0 \left( \frac{I_u}{1 + \alpha_1 I_u} + \frac{\eta I_e}{1 + \alpha_2 I_e} \right) + \varepsilon \beta C S_0 - k_0 E \right] \\ &\quad + \left[ \frac{k_2 k_3 + \eta k_3 \gamma_0 + \varepsilon q \gamma_0 (k_2 + \gamma_1)}{\varepsilon k_1 k_2} \right] (\sigma E - k_1 I_u) + \left[ \frac{k_0 k_1 + (\eta k_3 + \varepsilon q \gamma_1)}{\varepsilon k_0 k_1 k_2} \right] (\gamma_0 I_u - k_2 I_e) + q (\gamma_0 I_u + \gamma_1 I_e) - k_3 C \end{aligned} \quad (3.3.3)$$

$$\leq \left[ \frac{k_3 R_0}{\varepsilon} \right] (I_u + \eta I_e + \varepsilon C) - \frac{k_3 I_u}{\varepsilon} - \frac{\eta k_3 \gamma_0 I_u}{\varepsilon k_2} - \frac{\varepsilon q \gamma_0 (k_2 + \gamma_1) I_u}{\varepsilon k_2} + \frac{(\eta k_3 + \varepsilon q \gamma_1)}{k_2} (\gamma_0 I_u - k_2 I_e) + q (\gamma_0 I_u + \gamma_1 I_e) - k_3 C \quad (3.3.4)$$

$$= \frac{k_3 R_0}{\varepsilon} (I_u + \eta I_e + \varepsilon C) - \frac{k_3}{\varepsilon} (I_u + \eta I_e + \varepsilon C) \quad (3.3.5)$$

$$= \frac{k_3}{\varepsilon} (R_0 - 1) (I_u + \eta I_e + \varepsilon C) \quad (3.3.6)$$

since all the parameters and variables of the model are non-negative, it follows that  $\dot{F} \leq 0$  for  $R_0 \leq 1$  with  $\dot{F} = 0$  if and only if  $E = I_u = I_e = C = 0$ . Hence,  $F$  is a Lyapunov function on  $\Omega$ .

**Theorem 4** The endemic equilibrium of the reduced model, given by (3.1-3.6), is globally asymptotically stable (GAS) in  $\Omega$ , if  $R_0 > 1$ .

**Proof** Consider the reduced model in constructing the following nonlinear Lyapunov function:

$$\begin{aligned} F &= S - S^{**} - S^{**} \ln \left( \frac{S}{S^{**}} \right) + E - E^{**} - E^{**} \ln \left( \frac{E}{E^{**}} \right) + \frac{k_0}{\sigma} \left[ I_u - I_u^{**} - I_u^{**} \ln \left( \frac{I_u}{I_u^{**}} \right) \right] \\ &\quad + \frac{k_1}{q \gamma_0} \left[ C - C^{**} - C^{**} \ln \left( \frac{C}{C^{**}} \right) \right] \end{aligned} \quad (3.3.7)$$

Lyapunov derivatives gives;

$$\dot{F} = \dot{S} - \frac{S^{**}}{S} \dot{S} + \dot{E} - \frac{E^{**}}{E} \dot{E} + \frac{k_0}{\sigma} \left[ \dot{I}_u - \frac{I_u^{**}}{I_u} \dot{I}_u \right] + \frac{k_1}{q \gamma_0} \left[ \dot{C} - \frac{C^{**}}{C} \dot{C} \right] \quad (3.3.8)$$

substituting the reduced model,

$$\begin{aligned} \dot{F} = & \mu\omega(1-\nu C) + \psi V - \left[ \mu_0 + \beta \left( \frac{I_u}{1+\alpha_1 I_u} + \frac{\eta I_e}{1+\alpha_2 I_e} \right) \right] S - \frac{S^*}{S} \left[ \mu_0 + \beta \left( \frac{I_u}{1+\alpha_1 I_u} + \frac{\eta I_e}{1+\alpha_2 I_e} \right) \right] S \\ & + \left[ \beta \left( \frac{I_u}{1+\alpha_1 I_u} + \frac{\eta I_e}{1+\alpha_2 I_e} \right) + \varepsilon\beta C \right] S - k_0 E - \frac{E^*}{E} \left[ \beta \left( \frac{I_u}{1+\alpha_1 I_u} + \frac{\eta I_e}{1+\alpha_2 I_e} \right) + \varepsilon\beta C \right] S - k_0 E \\ & + \frac{k_0}{\sigma} \left[ \sigma E - k_1 I_u - \frac{I_u^*}{I_u} (\sigma E - k_1 I_u) \right] + \frac{k_1}{q\gamma_0} \left[ \frac{\mu\omega\nu C + q(\gamma_0 I_u + \gamma_1 I_e) - k_3 C}{C} \right] \end{aligned} \quad (3.3.9)$$

expanding the above, and also considering special case when  $\eta = 0$  then we have  $f(I_u)$ ;

$$\begin{aligned} \dot{F} = & A - (\mu_0 + \gamma_3)S - (\beta f(I_u) + \varepsilon\beta C)S - A \frac{S^{**}}{S} + (\mu_0 + \gamma_3)S^{**} + (\beta f(I_u) + \varepsilon\beta C)S^{**} \\ & + (\beta f(I_u) + \varepsilon\beta C)S - k_0 E - (\beta f(I_u) + \varepsilon\beta C) \frac{SE^{**}}{E} + k_0 E^{**} + k_1 I_u + \frac{k_1 \gamma_1 I_e}{\gamma_0} - \frac{k_1 k_3 C}{q\gamma_0} \\ & + \frac{k_1 I_u C^{**}}{C} - \frac{k_1 \gamma_1 I_e C^{**}}{\gamma_0 C} + \frac{k_1 k_3 C^{**}}{q\gamma_0} + k_0 E - \frac{k_0 k_1 I_u}{\sigma} - \frac{k_0 E I_u^{**}}{I_u} + \frac{k_0 k_1 I_u^{**}}{\sigma} \end{aligned} \quad (3.3.10)$$

simplifying and factorizing the common factors,

$$\begin{aligned} \dot{F} = & \left( A - (\mu_0 + \gamma_3)S \right) \left( 1 - \frac{S^{**}}{S} \right) + (\beta f(I_u) + \varepsilon\beta C)S^{**} \left( 1 - \frac{E^{**}S}{ES^{**}} \right) + k_0 E \left( \frac{E^{**}}{E} - 1 \right) \\ & + \left( k_1 I_u + \frac{k_1 \gamma_1 I_e}{\gamma_0} - \frac{k_1 k_3 C}{q\gamma_0} \right) \left( 1 - \frac{C^{**}}{C} \right) + \left( k_0 E - \frac{k_0 k_1 I_u}{\sigma} \right) \left( 1 - \frac{I_u^{**}}{I_u} \right) \end{aligned} \quad (3.3.11)$$

considering the following extract from the above;

$$\left( 1 - \frac{S^{**}}{S} \right) \leq 0, \quad \left( 1 - \frac{E^{**}S}{ES^{**}} \right) \leq 0, \quad \left( \frac{E^{**}}{E} - 1 \right) \leq 0, \quad \left( 1 - \frac{C^{**}}{C} \right) \leq 0, \quad \left( 1 - \frac{I_u^{**}}{I_u} \right) \leq 0. \quad (3.3.12)$$

Since all the parameters of the model are nonnegative, it follows that  $\dot{F} \leq 0$  for all  $R_0 > 1$  and with  $\dot{F} = 0$  if  $S = S^{**}$ ,  $E = E^{**}$ ,  $I_u = I_u^{**}$ , and  $C = C^{**}$ . Hence  $F$  is a Lyapunov function on  $\Omega$ .

#### 4.0 Numerical Simulation

We make use of Maple software to simulate numerically and determine the effect and behavior of the parameters of the model.

Table 4a

| Parameters |            |            |          |       | Model ( $R_0$ ) |          |
|------------|------------|------------|----------|-------|-----------------|----------|
| $\beta$    | $\gamma_3$ | $\gamma_2$ | $\omega$ | q     | DFE             | Remark   |
| 1.0        | 0.05       | 0.015      | 1.0      | 0.885 | 14.61905689     | unstable |
| 0.9        | 0.15       | 0.025      | 0.9      | 0.885 | 8.408021461     | unstable |
| 0.8        | 0.25       | 0.035      | 0.8      | 0.885 | 6.703960764     | unstable |
| 0.7        | 0.35       | 0.045      | 0.7      | 0.885 | 3.509192401     | unstable |
| 0.6        | 0.45       | 0.055      | 0.6      | 0.885 | 2.376014317     | unstable |
| 0.5        | 0.55       | 0.065      | 0.5      | 0.885 | 1.614546696     | unstable |
| 0.4        | 0.65       | 0.075      | 0.4      | 0.885 | 1.079135561     | unstable |
| 0.3        | 0.75       | 0.085      | 0.3      | 0.885 | 0.6893268001    | stable   |
| 0.2        | 0.85       | 0.095      | 0.2      | 0.885 | 0.3975633876    | stable   |
| 0.1        | 0.95       | 0.105      | 0.1      | 0.885 | 0.1742101439    | stable   |

#### 4.1 Discussion of Results

Simulations illustrate the asymptotic stability of DFE studied in section 3. The model described by equations (2.1 - 2.7) exhibit a rich dynamic. We observed that the biological basic reproduction number  $R_0$  is fundamental for the study of the basic dynamical properties. Applied to hepatitis B, the model suggests that infection rates play a great role in the description of the disease. Simulations conducted confirm our results and suggest possible way to curb the outbreak of the disease epidemic. To control HBV infection, we would like to see what parameters can reduce the basic reproduction number. From table 4(a), we see that as  $\beta$  (effective contact rate) decreases,  $R_0$  decreases. Consequently,  $R_0$  decreases as  $1 - \omega$ ,  $\gamma_2$  and  $\gamma_3$  increase in the model. Therefore, we observed that the immunization of both newborn carrier and susceptible individuals is an efficient intervention.

#### 5.0 Reference

- [1] Barker LF, Shulman NR, Murray R, Hirschman RJ, Ratner F, Diefenbach WC, Geller HM (1996). "Transmission of serum hepatitis. 1970". *Journal of the American Medical Association* 276 (10):841-844. doi:10.1001/jama.276.10.841.
- [2] Chang MH (June 2007). "Hepatitis B virus infection". *Semin Fetal Neonatal Med* 12 (3): 160-167. doi:10.1016/j.siny.2007.01.013.
- [3] Edmunds, W.J., Medley, G.F., Nokes, D.J., Hall, A.J., Whittle, H.C., 1993. The influence of age on the development of the hepatitis B carrier state. *Proc. R. Soc. Lond. B* 253, 197001.
- [4] Edmund, W. J., Medley, G. F., Nokes, D. J., O'callaghan, C. J., Whittle, H. C., Hull, A. J. (1996). Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. *Epidemiology and Infection*, 117(2), 313-325.
- [5] Gane, E. (2005). Screen for chronic hepatitis B infection in New Zealand: unfinished business. *The New Zealand Medical Journal*, 118(1211). <http://www.nzma.org.nz/journal/118-1211/1344/>.
- [6] Ganem, D., Prince, A. M. (2004). Mechanics of disease: hepatitis B virus infection-natural history and clinical consequences. *New England Journal of Medicine*, 350(11), 1118-1129.
- [7] Goldstein, S. T., Zhou, F., Hadler, S. C., Bell, B. P., Mast, E. E., Margolis, H. S. (2005). A mathematical model to estimate global hepatitis B burden and vaccination impact. *International Journal of Epidemiology*, 34, 1329-1339.
- [8] Hou, J., Liu, Z., Gu, F., 2005. Epidemiology and prevention of hepatitis B virus infection. *Int. J. Med. Sci.* 2 (1), 50-57.
- [9] Lan Zou, Weinian Zhang Shigui Ruan, 2010. Modeling the transmission dynamics and control of hepatitis B virus in China *Journal of Theoretical Biology* 262 (2010) 330-338 control measures. *J. Viral. Hepat.* 11, 97-107.
- [10] McManhon B. J., Alward W. L. M., Hall D. B. et al. Acute hepatitis B virus infection: Relation of age to clinical expression of disease and subsequent development of the carrier state. *J Infect Dis* 1985; 151:599-603.

- [11] Wang, X.J., Zhang, R.Z., Hu, Y.S., Liang, X.F., 2004. Analysis on epidemic status of viral hepatitis in China: the report from Chinese Center for Disease Control and Prevention. *Dis. Sur.* 19, 290-292.
- [12] Williams, R., 2006. Global challenges in liver disease. *Hepatology*. 44 (3), 521-526.
- [13] WHO World Health Organization Report, (2004)

## 1.0

The r  
major  
Other  
D.J.a  
Many  
sprea  
epide  
seem  
Conti  
disea  
has l  
Phil  
The  
deve  
disea  
susce  
cont  
disea  
prot  
Stud

Con